Literature DB >> 12871461

Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment.

D Ferro1, M Saliola, P L Meroni, G Valesini, C Caroselli, D Praticò, G A Fitzgerald, Y Shoenfeld, F Violi.   

Abstract

In a first study, we performed a cross-sectional analysis of urinary excretion of isoprostanes, IPF(2alpha-III) and (VI), and monocyte tissue factor (TF) antigen and activity between 11 antiphospholipid (APL) antibody-positive patients and 13 APL negative subjects. In a second study, 11 APL positive patients were randomly supplemented either with (n = 6) or without (n = 5) antioxidants (vitamin E at 900 IU day(-1), vitamin C at 2000 mg day(-1)) for 6 weeks. In a third study, TF and superoxide anion were measured in human monocytes incubated with anti-beta(2) glycoprotein 1 (beta(2)GP(1)) or control IgG, either with or without vitamin E. APL-positive patients had higher values of isoprostanes (P < 0.05) and monocyte TF antigen (P = 0.001) and activity (P = 0.0001) than APL-negative subjects. Only in APL positive patients did monocyte TF antigen correlate significantly with IPF(2alpha-III) (rho 0.79; P < 0.003) and IPF(2alpha-VI) (rho = 0.87; P < 0.0001). In patients who received antioxidant supplementation, we found a significant decrease of isoprostanes (P < 0.05) and monocyte TF antigen (P < 0.01) and activity (P < 0.007). In vitro experiments demonstrated that anti-beta(2)GP(1) antibodies dose-dependently enhanced the monocyte production of the superoxide anion and TF, which were significantly inhibited by vitamin E. This study demonstrates that in APL-positive patients, oxidative stress contributes to activate the clotting system via over-expression of monocyte TF. We suggest that anti-beta(2)GP(1) antibodies could play a pivotal role by enhancing the monocyte production of oxygen free radicals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871461     DOI: 10.1046/j.1538-7836.2003.00108.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  6 in total

1.  Redox-regulation of haemostasis in hypoxic exercising humans: a randomised double-blind placebo-controlled antioxidant study.

Authors:  Lewis Fall; Julien V Brugniaux; Danielle Davis; Christopher J Marley; Bruce Davies; Karl J New; Jane McEneny; Ian S Young; Damian M Bailey
Journal:  J Physiol       Date:  2018-08-29       Impact factor: 5.182

Review 2.  Antiphospholipid antibody effects on monocytes.

Authors:  Alisa S Wolberg
Journal:  Curr Rheumatol Rep       Date:  2007-06       Impact factor: 4.686

3.  Evaluation of the hypolipidemic activity of 6,7-dimethoxycoumarin on placental tissue factor mRNA expression in experimental anti-phospholipid syndrome.

Authors:  Annamalai Amarnath; Veeraval Lenin; Govindaraju Archunan
Journal:  Pharmacogn Mag       Date:  2013-07       Impact factor: 1.085

4.  Transcriptome alterations of mitochondrial and coagulation function in schizophrenia by cortical sequencing analysis.

Authors:  Kuo-Chuan Huang; Ko-Chun Yang; Han Lin; Theresa Tsun-Hui Tsao; Sheng-An Lee
Journal:  BMC Genomics       Date:  2014-12-08       Impact factor: 3.969

5.  Anti-β2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies exert similar pro-thrombotic effects in peripheral blood monocytes and endothelial cells.

Authors:  A Cifù; R Domenis; C Pistis; F Curcio; M Fabris
Journal:  Auto Immun Highlights       Date:  2019-04-06

Review 6.  The Pathophysiology of The Antiphospholipid Syndrome: A Perspective From The Blood Coagulation System.

Authors:  R Arreola-Diaz; A Majluf-Cruz; L E Sanchez-Torres; J Hernandez-Juarez
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.